within Pharmacolibrary.Drugs.ATC.C;

model C08CA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.45,
    Cl             = 0.62 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.00065,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Nifedipine is a dihydropyridine calcium channel blocker primarily used for the treatment of hypertension and angina pectoris. It causes vasodilation by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle. It is an approved drug and remains widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after a single oral immediate-release dose.</p><h4>References</h4><ol><li><p>Raemsch, KD, &amp; Sommer, J (1983). Pharmacokinetics and metabolism of nifedipine. <i>Hypertension (Dallas, Tex. : 1979)</i> 5(4 Pt 2) II18–II24. DOI:<a href=&quot;https://doi.org/10.1161/01.hyp.5.4_pt_2.ii18&quot;>10.1161/01.hyp.5.4_pt_2.ii18</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6862586/&quot;>https://pubmed.ncbi.nlm.nih.gov/6862586</a></p></li><li><p>Sanusi, AA, et al., &amp; Tita, ATN (2024). Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension. <i>Obstetrics and gynecology</i> 144(1) 126–134. DOI:<a href=&quot;https://doi.org/10.1097/AOG.0000000000005613&quot;>10.1097/AOG.0000000000005613</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38949541/&quot;>https://pubmed.ncbi.nlm.nih.gov/38949541</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C08CA05;
